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Abstract
Background: Uterine serous endometrial intraepithelial carcinoma (SEIC) is an immediate precursor of invasive
carcinoma. The majority of stage IA SEICs are curable, but those with latent peritoneal metastasis and/or capillary
lymphatics invasion may have poor prognoses Careful pathologic staging is thus needed to predict the risk of
recurrence and to determine postoperative therapeutic strategies.
Case Presentation: A 71-year-old woman was hospitalized for the treatment of peritoneal carcinoma. She had
undergone total hysterectomy and bilateral salpingo-oophorectomy due to SEIC (stage IA) at age 63 years, and had
received medical check-ups every year since. Elevated serum CA125 (184 U/mL) was detected for the first time 8 years
after surgery. A thorough workup revealed no potential primary lesion other than that in the peritoneum. Tumor
reduction surgery was performed. Histologic analysis of the peritoneal lesion was high-grade serous carcinoma. The
peritoneal carcinoma was diffusely immunostained for p53; thus, possible recurrence of SEIC was suspected. Tumor
DNAs were microdissected from the uterine and peritoneal lesions and p53 mutation analysis was done. SEIC and
peritoneal carcinomas had distinct p53 mutations that were mutually exclusive.
Conclusions: The present case raised a concern about the difficulty of histologic staging for SEICs. Although
SEICs confined to the uterine endometrium in most cases predict a good prognosis, microscopic metastasis
to the peritoneum may not be detectable at hysterectomy. If secondary malignancies of a serous phenotype
develop years later, comprehensive reexamination of SEIC is mandated, with the help of DNA analysis.
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Background
Uterine serous endometrial intraepithelial carcinoma
(SEIC) is a unique malignancy that predominantly
occurs in postmenopausal women [1, 2]. In most cases,
patients with SEIC confined to the uterus have favorable
prognoses [2, 3]; however, SEIC sometimes disseminates
in the peritoneal cavity and/or metastasizes to distant
sites [4, 5]. Primary peritoneal serous carcinoma is
another malignancy that often involves gynecologic
organs. The differential diagnosis includes metastasis
from occult tubal intraepithelial serous carcinoma and
SEIC. The majority of gynecologic malignancies of
high-grade serous phenotype are histologically indistin-
guishable from peritoneal serous carcinoma. Multifocal
occurrence should also be considered in peritoneal
serous carcinoma [6]. Therefore, it is occasionally diffi-
cult to distinguish between peritoneal serous carcinomas
primary lesion(s) and SEIC. Herein we describe an
unusual case of peritoneal carcinoma in a patient previ-
ously diagnosed with SEIC.
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Case presentation
A 71-year-old woman was referred to us due to elevated
serum CA125 (184 U/mL). She had undergone hysterec-
tomy and bilateral salpingo-oophorectomy 8 years previ-
ously due to SEIC and multiple leiomyomas (Fig. 1a).
The SEIC lesion had been confined to the endometrium
(FIGO Stage IA); however, peritoneal cytology was
borderline (Class IIIb, atypical glandular cells). She had
undergone periodic surveillance without postoperative
chemotherapy. An elevated serum CA125 level was de-
tected for the first time 8 years after hysterectomy and
bilateral salpingo-oophorectomy. Computed tomography
revealed a 5 × 4 cm cystic lesion in the abdominal cavity.
A thorough medical workup denied any possible primary
lesions in the body except for that in the peritoneum.
The patient was suspected to either have primary peri-
toneal carcinoma or recurrent SEIC. Tumor debulking
surgery was performed, and the cystic lesion and one
disseminated nodule were resected. Inside of the cyst,
papillary tumor proliferation was observed (Fig. 1b). The
patient received 6 cycles of adjuvant chemotherapy, and
complete remission has been achieved for 12 months.
Microscopically, peritoneal tumor cells had a morpho-
logic appearance of high-grade serous carcinoma. The
tumor cells proliferated in either gland-like or exophytic
papillary patterns. Slit-like spaces were observed. Tumor
cells had pleomorphic nuclei and eosinophilic cytoplasm,
and the cyst wall was composed of a hyalinized mem-
brane lined by one or a few epithelial cells. Although
papillary tumors in the cyst arose continuously from the
inner lining cells, it was difficult to determine by
histology whether the peritoneal lesion was primary ser-
ous carcinoma or recurrent SEIC. Immunohistochemical
analysis revealed that the peritoneal carcinoma was dif-
fusely positive for cytokeratin 7, p53, and PAX 8, and
was partially positive for WT-1, estrogen receptor (ER),
and progesterone receptor (PgR).
We then reviewed the uterus and adnexa resected
8 years previously. Although the fallopian tubes and
ovaries were not meticulously cut at 2-mm intervals, no
malignant signs were present in the adnexa. The tubal
mucosa and ovarian surface were normal in size and
morphology, with atrophic features. Neither intraepithelial
carcinoma/dysplasia nor disseminated carcinoma was
detectable in the adnexa. The inner surface of the uter-
ine endometrium was distorted due to submucosal leio-
myoma. Neither gross endometrial lesions nor polyps
were identified. Atrophic normal endometrium was
detected adjacent to the SEIC, and the SEIC was dis-
tributed in a noninvasive manner. No lymphovascular
space invasion was observed in the resected organs. Im-
munohistochemical analysis revealed that these glands
were diffusely positive for p53 and PAX8, and negative
for WT-1, ER, and PgR. The Ki-67 proliferation index
was 70 %. The presence of a p53 signature with an ele-
vated Ki-67 proliferation index was consistent with the
histologic diagnosis of SEIC.
The patient did not have any medical history associ-
ated with familial cancer, such as hereditary breast ovar-
ian carcinoma syndrome. Although 8 years had passed
with a disease-free condition, possible metastatic carcin-
oma from the SEIC could not be completely denied. To
investigate whether the two lesions were independent or
represented metastasis from one site to another, SEIC
and peritoneal carcinoma cells were microdissected, re-
spectively. Written informed consent for molecular ana-
lysis of the surgical specimens was obtained from the
patient. DNA of each lesion was extracted. Exons 5–8 of
p53 and exons 8–9 of FBXW7 were amplified by poly-
merase chain reaction. The SEIC was revealed to have a
p53 mutation at p.M169T, whereas the peritoneal
carcinoma had a mutation at p.R273H (Fig. 2). These
mutations were mutually exclusive. No mutations in
exons 8–9 of FBXW7 were detected in either tumors.
Discussion
Very little information is available regarding whether
early-stage SEIC could potentially relapse 8 years after
total hysterectomy and bilateral salpingo-oophorectomy
[7]. Since both unifocal and multifocal serous carcin-
omas have been reported in gynecologic serous carcin-
omas, we considered a possible relapse in the present
case. One report has been published in which a SEIC
without stromal invasion resulted in distant metastasis
3 years after surgical intervention, in which both lesions
shared an identical p53 mutation [8]. Although differential
immunostaining patterns of ER, PgR, and WT-1 between
peritoneal serous carcinomas and SEIC are helpful for
(See figure on previous page.)
Fig. 1 Macroscopic and microscopic features of serous endometrial intraepithelial carcinoma (SEIC) and peritoneal carcinoma. a The resected uterus
had several leiomyomas occupying the uterine cavity (left). The cut surface of the vertical axis is shown (right). The surface in the dotted rectangle
indicates the SEIC lesion. b The peritoneal carcinoma developed as a cyst on the surface of intestinal mesenchyme (left). Inside of the cyst, a papillary
lesion was detected (right). c Hematoxylin-eosin (HE) staining of the SEIC in atrophic endometrium. Hyalinized submucosal leiomyoma is
observed in the adjacent tissue. d HE staining of the peritoneal carcinoma. Proliferating papillary tumor cells with atypia are observed. e,
f Immunostaining for p53 in the SEIC (E) and the peritoneal carcinoma (F). Both lesions show diffusely positive staining. g, h Immunostaining for WT-1
in the SEIC (G) and the peritoneal carcinoma (H). The SEIC is negative for WT-1 (G), whereas the peritoneal carcinoma shows focal positive staining (H).
Serial staining sections are shown
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determining the origin, an argument exists against the
utility of WT-1 for differential diagnosis [9, 10]. The
WT-1 immunostaining pattern in the present periton-
eal carcinoma was focal and weak; thus, more reliable
information was required to make a conclusive diagnosis.
Mutually-exclusive p53 mutation patterns strongly sug-
gested that the peritoneal lesion was a second pri-
mary cancer. If the SEIC had metastasized to the
peritoneal cavity, both lesions would have shared
identical mutation. Although secondary lesions poten-
tially have different mutations, it is unlikely that the
mutation of the primary lesion is normalized during
metastasis. The present case alerted us to not associ-
ate the peritoneal serous carcinoma with the early-
stage SEIC that occurred 8 years previously solely by
histologic comparison.
It remains unclear whether the peritoneal carcinoma
developed by chance or whether this patient was at risk
of developing multifocal serous-type cancers. It is
unlikely that she had mutations in the BRCA genes, be-
cause none of her siblings experienced cancers of the
breast, ovary, or peritoneum. Since the peritoneal
cytology had been Class IIIb at initial surgery, atypical
peritoneal cells might have already been present 8 years
previously. We also considered possible occult intrae-
pithelial carcinoma in the adnexa. The lack of macro-
scopic signs of neoplasms in the ovary and fallopian
tubes allowed us to perform usual sectioning of the
adnexa. Lymph node staging was also not performed.
Currently, no guidelines about whether complete
sectioning of the adnexa should be performed or
whether usual pathologic sectioning is sufficient for sta-
ging of SEICs exist. Although the possibility is very low
that occult serous tubal/ovarian intraepithelial carcin-
oma disseminated and developed in the peritoneum
8 years after total resection, the present case alerted us
to examine both adnexa and extra-pelvic lesions care-
fully in SEICs.
Conclusion
We have described a case of metachronous peritoneal
carcinoma that occurred 8 years after SEIC. Based on
clinicopathologic findings and p53 mutation patterns,
we concluded that the two lesions were most likely
independent. Limited information is available about
possible recurrence of early-stage SEIC after 5 years
of follow-up. Since microscopic metastases of SEICs
in the adnexa and/or extra-pelvic organs lead to poor
prognoses [3], gynecologists and pathologists should
carefully investigate the possible presence of micro-
scopic lesions in organs other than the uterus as well
as lymphovascular space invasion in SEICs. Long-
term follow-up will be beneficial not only for patients
with advanced SEICs but also for those who are diag-
nosed with early-stage SEICs for a better understand-
ing of the postoperative risks of serous carcinomas in
the peritoneal cavity.
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Fig. 2 Distinct p53 mutation patterns in SEIC and peritoneal carcinoma. (Upper sequences) p53 exon 5 sequences of the SEIC (left) and the peritoneal
carcinoma (right). A somatic mutation from ATG to ACG (arrow) was detected in the SEIC, predicting the amino acid change p.Met169Thr. The peritoneal
carcinoma had a wild-type sequence at this position. (Lower sequences) p53 exon 8 sequences of the SEIC (left) and the peritoneal carcinoma (right). A
somatic mutation from CGT to CAT (arrow) was detected in the peritoneal carcinoma, predicting the amino acid change p.Arg273His. SEIC had a wild-type
sequence at this position
Furuya et al. Diagnostic Pathology  (2016) 11:130 Page 4 of 5
Acknowledgements
The authors would like to thank Ms. H. Soeda, M. Kawashima, and the staff of
the pathology laboratories at Yokohama City University Hospital for their
excellent technical assistance.
Funding
This work was supported in part by JSPS KAKENHI grant number 26460422
(to M.F.) in the writing of the manuscript.
Availability of data and materials
The datasets generated during and/or analyzed during the current study are
not publicly available due to a privacy policy, but are available from the
corresponding author on reasonable request.
Authors' contributions
MF, TS, and RT analyzed and interpreted the data. NRY, MY, and EM
contributed to clinical management. MF, TS, NRY, MY, and EM contributed to
writing the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent for publication of their clinical details and/or
clinical images was obtained from the patient. A copy of the consent form is
available for review by the Editor of this journal.
Ethics approval and consent to participate
The studies of somatic mutation was approved by the Institutional Review
Boards of Yokohama City University (No. 24-109).
Author details
1Department of Molecular Pathology, Yokohama City University Graduate
School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
2Departments of Pathology, Keiyu, Hospital, Yokohama, Japan. 3Medical
Mycology Research Center, Chiba University, Chiba, Japan. 4Department of
Gynecology, Yokohama City University Graduate School of Medicine,
Yokohama, Japan.
Received: 21 July 2016 Accepted: 9 November 2016
References
1. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and
progression. Int J Clin Exp Pathol. 2009;2(5):411–32.
2. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous
carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol.
2000;24(6):797–806.
3. Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine
serous carcinoma: a clinicopathological study of 40 cases. Mod Pathol.
2005;18(1):75–82.
4. Gehrig PA, Groben PA, Fowler Jr WC, Walton LA, Van Le L. Noninvasive papillary
serous carcinoma of the endometrium. Obstet Gynecol. 2001;97(1):153–7.
5. Chan JK, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev SA, et al.
Significance of comprehensive surgical staging in noninvasive papillary
serous carcinoma of the endometrium. Gynecol Oncol. 2003;90(1):181–5.
6. Muto MG, Welch WR, Mok SC, Bandera CA, Fishbaugh PM, Tsao SW, et al.
Evidence for a multifocal origin of papillary serous carcinoma of the
peritoneum. Cancer Res. 1995;55(3):490–2.
7. Hou JY, McAndrew TC, Goldberg GL, Whitney K, Shahabi S. A clinical and
pathologic comparison between stage-matched endometrial intraepithelial
carcinoma and uterine serous carcinoma: is there a difference? Reprod Sci.
2014;21(4):532–7.
8. Baergen RN, Warren CD, Isacson C, Ellenson LH. Early uterine serous carcinoma:
clonal origin of extrauterine disease. Int J Gynecol Pathol. 2001;20(3):214–9.
9. Euscher ED, Malpica A, Deavers MT, Silva EG. Differential expression of WT-1
in serous carcinomas in the peritoneum with or without associated serous
carcinoma in endometrial polyps. Am J Surg Pathol. 2005;29(8):1074–8.
10. Hirschowitz L, Ganesan R, Mccluggage WG. WT1, p53 and hormone
receptor expression in uterine serous carcinoma. Histopathology. 2009;55(4):
478–82.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Furuya et al. Diagnostic Pathology  (2016) 11:130 Page 5 of 5
